Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hayden Locke, CEO Emmerson plc, a low cost high margin potash investment
Richard Slape, Oil consultant - Avoiding Losers and Picking Winners, his personal strategy


ShareCast News


Oxford Biomedica swings to positive earnings in 2018

Thu, 14th Mar 2019 14:16


(Sharecast News) - Gene and cell therapy group Oxford Biomedica reported a 72% increase in gross income in its preliminary results for the year ended 31 December on Thursday, to 67.9m.

The London-listed firm said its revenue rose 78% to 66.8m, while adjusted operating expenses were 38% higher at 31.7m.

Operating EBITDA stood at 13.4m for the year, swinging from an operating EBITDA loss of 1.9m in 2017.

Licence income stood at 18.3m, which the board said was due to the Axovant Sciences and Bioverativ deals, which was segmented by product at 10.2m and platform at 8.1m.

A 6m gain was recognised on revaluation of investment in Orchard Therapeutics, the board noted.

Cash inflow before financing activities rose to 2.8m from 1.0m, with cash as at 31 December standing at 32.2m, up from 14.3m year-on-year, which the directors said reflected "significantly improved" trading performance and the placing to raise gross proceeds of 20.5m.

That was raised from new and existing investors through a placing to fund the proposed expansion and fit-out of the additional bioprocessing facilities at a new facility in Oxford, with capital expenditure increasing to 10.8m from 2.0m.

A total of 5m in capital expenditure grants was received from Innovate UK during the year, to support the UK's efforts to produce viral vectors and ensure adequate supply to service expected demand.

Oxford Biomedica completed a share consolidation in May, to reduce the number of issued ordinary shares in the company by a factor of 50.

"Oxford Biomedica is at the centre of a burgeoning industry in which life-changing, curative treatment has become a therapeutic reality," said chief executive officer John Dawson.

"In the past year, alongside landmark regulatory approvals and launches in the sector, we have seen our strategy delivering with significant revenue-generating deals for both our platform and our products, and we continue to scale our capacity to meet the expected demand from future growth.

"We are confident that our focus on platform development, pipeline enhancement, technology innovation and operational delivery puts us on the right trajectory to capitalise on our market leading position."


Related Shares:



Back to ShareCast News


Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk




Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.